Filing Details
NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event.
8k filedNASDAQ:NAMS
NewAmsterdam Pharma Co N.V. (NAMS) Reports Material Event to SEC
Filing Details NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) filed a Form 8-K with the Securities and Exchange Commission on July 24, 2026, disclosing a material event. Market Context…
Market Context
NewAmsterdam Pharma Co N.V.'s stock currently trades at $29.64 with a market capitalization of $4.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for NewAmsterdam Pharma Co N.V.'s stock.
All SEC filings for NewAmsterdam Pharma Co N.V. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NAMS Stock Page
Frequently Asked Questions
Where can I read NAMS's SEC filings?
Browse all filings on our NAMS SEC filings page.
What types of SEC filings does NewAmsterdam Pharma Co N.V. file?
Public companies like NewAmsterdam Pharma Co N.V. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.